
Release date: 2024-08-07 15:13:01 Article From: Lucius Laos Recommended: 281
Exkivity is an innovative, oral, small molecule tyrosine kinase inhibitor (TKI) primarily used for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
Exkivity is a targeted therapy for non-small cell lung cancer (NSCLC) with specific genetic mutations with clear criteria for recommended doses. Specifically, the recommended dose of Exkivity is 160 mg orally daily until the disease progresses or the patient is unable to tolerate the adverse effects of the drug.
To ensure the efficacy and safety of the drug, patients should try to take Exkivity at the same time each day and may choose to take it with or without food depending on their individual circumstances. Patients should pay attention to follow the doctor's instructions and not change the dose or discontinue the drug at will, so as not to adversely affect the treatment effect.
For patients with non-small cell lung cancer, psychological care is particularly important.
It is advisable to actively seek the assistance of a professional psychologist. These therapists with deep professional knowledge are able to listen patiently to the patient's heart, deeply understand their inner troubles, and help the patient release the accumulated bad emotions through effective communication. Their support not only promotes self-awareness but also strengthens resilience in the face of illness and gives patients a stronger mindset to cope with challenges.
Close cooperation between family members and medical staff is also an indispensable part of psychological care. The medical team should take the initiative to establish a one-to-one communication bridge with the patient, carefully observe the patient's physical and mental state, and tailor a personalized psychological care plan for the patient.
By patiently explaining disease-related knowledge, patients can correct possible misunderstandings and help them establish a scientific concept of disease. During this period, family members should become the most solid backing for patients, surround patients with love and understanding, help them relieve the haze in their hearts, and jointly create a positive treatment atmosphere.
【Warm tips】When patients buy generic drugs, they should choose formal channels to ensure the quality and safety of the drugs. Avoid purchasing counterfeit products from informal sources.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:2622025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:4832024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:2672025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:2772025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:2582025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:3032025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:2652025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:2442025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: